SAGE Therapeutics to Participate in the Goldman Sachs 36th

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SAGE Therapeutics to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE ), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., chief executive officer of SAGE will participate in a question and answer session at the Goldman Sachs 36 th Annual Global Healthcare Conference at 10 a.m. PT on Wednesday, June 10, 2015.

The live webcast can be accessed on the investor page of SAGE's website at investor.sagerx.com . A replay of the webcast will also be archived on SAGE's website following the conference.

About SAGE Therapeutics

SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. SAGE's lead program, SAGE-547, is entering Phase 3 clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the Company is developing in its portfolio of potential anti-seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com .

Forward-Looking Statements

Various statements in this release concerning SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding SAGE-547 as a treatment for SRSE, essential tremor and severe postpartum depression constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. It should be noted that there is only limited data concerning the safety and efficacy of SAGE-547. These data may not be repeated or observed in future trials involving SAGE-547. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in SAGE's annual report on Form 10-K for the fiscal year ended December 31, 2014 and quarterly report on Form 10-Q for the quarter ended March 31, 2015, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.

Investor Contact: Paul Cox, SAGE Therapeutics 617-299-8377 Media Contact: Dan Budwick, Pure Communications 973-271-6085

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 443

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 191

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 348

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 430

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 280

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Comparison of Amazon.com with Leading Retail Industry Peers

Updated Category News Views 395

Understanding Amazon.com in the Retail Market In an ever-evolving business environment, investors must carefully analyze leading companies. This article presents a detailed evaluation of Amazon.com Inc (NASDAQ: AMZN) and its position compared to competitors in the Broadline Retail industry. By investigating vital financial metrics and market dynamics, we aim to offer...

Continue Reading
Legal Triumph Brings Significant Gains for Safe & Green Holdings

Updated Category News Views 156

Significant Legal Victory for Safe & Green Holdings Safe & Green Holdings Corp. (NASDAQ: SGBX), a prominent player in the modular building sector, recently celebrated a notable victory in a legal battle that promises to deliver substantial value to its shareholders. The company secured a favorable judgment against EDI International, PC, and PVE, LLC, in a case overseen by...

Continue Reading
Innovative Risk Measure for Joint Replacement Surgeons

Updated Category News Views 107

New Risk-Adjusted Measure for Orthopaedic Surgery The American Joint Replacement Registry (AJRR) has announced the launch of an innovative risk-adjusted revision rate measure designed to support orthopaedic surgeons in evaluating their outcomes. This measure is now available through the RegistryInsights platform and aims to provide more equitable and valuable feedback...

Continue Reading
Bybit's Innovative Indices Trading Enhances Investor Opportunities

Updated Category News Views 77

Bybit Expands Trading Options for Cryptocurrency Investors Bybit, recognized among the leading cryptocurrency exchanges worldwide, has recently enhanced its MetaTrader 5 (MT5) platform by introducing the capability to trade global indices using USDT. This significant feature offers users a unique opportunity to engage with traditional markets while still functioning...

Continue Reading
Shoe Palace Enhances Growth and Efficiency with Centric PLM

Updated Category News Views 303

Shoe Palace Enhances Growth and Efficiency with Centric PLM Centric PLM centralizes product development, providing a single, actionable source of truth for retailers striving for innovation. Shoe Palace, a respected name in footwear and fashion retail, has taken a significant step forward by adopting Centric Product Lifecycle Management (PLM) software. This transition...

Continue Reading